Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) (PACE)
A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia
Sponsor: Ariad Pharmaceuticals
This PHASE2 trial investigates Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia and is currently completed. Ariad Pharmaceuticals leads this study, which shows 13 recorded versions since 2010 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Mar 2019 — Feb 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Dec 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ariad Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Amsterdam, Netherlands , Barcelona, Spain , Berlin, Germany , Bologna, Italy , Bordeaux, France , Box Hill, Australia , Brussels, Belgium , East Melbourne, Australia , Frankfurt, Germany and 32 more locations